Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 3.3%

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) shares were up 3.3% on Tuesday . The company traded as high as $13.19 and last traded at $12.90. Approximately 191,207 shares were traded during mid-day trading, a decline of 46% from the average daily volume of 355,289 shares. The stock had previously closed at $12.49.

Analyst Upgrades and Downgrades

YMAB has been the subject of several recent research reports. Canaccord Genuity Group upgraded shares of Y-mAbs Therapeutics to a “strong-buy” rating in a report on Tuesday, August 13th. BMO Capital Markets cut their target price on Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 13th. Morgan Stanley lowered their price target on Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating for the company in a research report on Tuesday, August 13th. Canaccord Genuity Group reissued a “buy” rating and set a $26.00 price objective on shares of Y-mAbs Therapeutics in a research report on Tuesday, August 13th. Finally, Cantor Fitzgerald began coverage on shares of Y-mAbs Therapeutics in a report on Friday. They issued an “overweight” rating and a $20.00 target price for the company. Two investment analysts have rated the stock with a sell rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.38.

Y-mAbs Therapeutics Price Performance

The stock’s 50-day moving average is $11.86 and its two-hundred day moving average is $13.71. The company has a market cap of $602.14 million, a P/E ratio of -26.57 and a beta of 0.66.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its earnings results on Monday, August 12th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.08). The business had revenue of $22.80 million for the quarter, compared to analysts’ expectations of $23.09 million. Y-mAbs Therapeutics had a negative net margin of 28.44% and a negative return on equity of 24.88%. During the same period in the prior year, the company posted ($0.14) earnings per share. On average, analysts predict that Y-mAbs Therapeutics, Inc. will post -0.55 EPS for the current year.

Insider Buying and Selling

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 35,000 shares of Y-mAbs Therapeutics stock in a transaction on Monday, June 10th. The shares were sold at an average price of $12.03, for a total value of $421,050.00. Following the sale, the insider now directly owns 197,681 shares in the company, valued at approximately $2,378,102.43. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Y-mAbs Therapeutics news, insider Thomas Gad sold 35,000 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $12.03, for a total transaction of $421,050.00. Following the sale, the insider now directly owns 197,681 shares of the company’s stock, valued at $2,378,102.43. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Bo Kruse sold 31,371 shares of the business’s stock in a transaction that occurred on Friday, May 31st. The shares were sold at an average price of $12.07, for a total value of $378,647.97. Following the transaction, the chief financial officer now directly owns 210,877 shares in the company, valued at approximately $2,545,285.39. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 74,444 shares of company stock worth $903,925. 21.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Hedge funds have recently modified their holdings of the company. Campbell & CO Investment Adviser LLC purchased a new position in shares of Y-mAbs Therapeutics in the 4th quarter valued at about $562,000. Squarepoint Ops LLC boosted its position in Y-mAbs Therapeutics by 143.4% during the second quarter. Squarepoint Ops LLC now owns 126,389 shares of the company’s stock worth $1,527,000 after purchasing an additional 74,452 shares in the last quarter. Millennium Management LLC grew its holdings in Y-mAbs Therapeutics by 23.8% in the second quarter. Millennium Management LLC now owns 349,784 shares of the company’s stock valued at $4,225,000 after purchasing an additional 67,233 shares during the period. Dimensional Fund Advisors LP increased its position in shares of Y-mAbs Therapeutics by 15.7% in the second quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock valued at $5,853,000 after buying an additional 65,732 shares in the last quarter. Finally, Los Angeles Capital Management LLC raised its stake in shares of Y-mAbs Therapeutics by 17.3% during the 4th quarter. Los Angeles Capital Management LLC now owns 356,530 shares of the company’s stock worth $2,432,000 after buying an additional 52,610 shares during the period. 70.85% of the stock is owned by hedge funds and other institutional investors.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.